Cahill Financial Advisors Inc. Buys Shares of 5,514 Solventum Co. (NYSE:SOLV)

Cahill Financial Advisors Inc. bought a new stake in Solventum Co. (NYSE:SOLV) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,514 shares of the company’s stock, valued at approximately $292,000.

A number of other hedge funds also recently added to or reduced their stakes in SOLV. Fifth Lane Capital LP purchased a new position in shares of Solventum during the 1st quarter worth approximately $826,000. Boit C F David purchased a new position in shares of Solventum during the 1st quarter worth approximately $152,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in shares of Solventum during the 1st quarter worth approximately $5,747,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Solventum during the 1st quarter worth approximately $209,000. Finally, LRI Investments LLC purchased a new position in shares of Solventum during the 1st quarter worth approximately $43,000.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on SOLV shares. BTIG Research started coverage on shares of Solventum in a research note on Thursday, September 5th. They set a “neutral” rating for the company. The Goldman Sachs Group raised their price objective on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Wells Fargo & Company dropped their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. Morgan Stanley decreased their target price on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Finally, Argus started coverage on shares of Solventum in a research report on Monday, June 24th. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. According to MarketBeat.com, Solventum currently has a consensus rating of “Hold” and an average target price of $58.25.

Solventum Stock Performance

Shares of NYSE SOLV opened at $67.03 on Tuesday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The stock’s 50 day moving average price is $57.26. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.10. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.05 billion. The business’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts forecast that Solventum Co. will post 6.38 earnings per share for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.